161 related articles for article (PubMed ID: 26780597)
1. Preservation of macular structure and function after intravitreal aflibercept for choroidal neovascularization associated with serpiginous choroiditis.
Schatz P; Skarin A; Lavaque AJ; Lima LH; Arevalo JF
Acta Ophthalmol; 2016 Dec; 94(8):839-841. PubMed ID: 26780597
[No Abstract] [Full Text] [Related]
2. Aflibercept for inflammatory choroidal neovascularization with persistent fluid on intravitreal ranibizumab therapy.
Hernández-Martínez P; Dolz-Marco R; Alonso-Plasencia M; Abreu-Gonzalez R
Graefes Arch Clin Exp Ophthalmol; 2014 Aug; 252(8):1337-9. PubMed ID: 24789465
[No Abstract] [Full Text] [Related]
3. Intravitreal aflibercept for refractory choroidal neovascularization secondary to angioid streaks.
Tetikoglu M; Sagdik HM; Aktas S; Ozcura F
Eye (Lond); 2016 Jun; 30(6):894-5. PubMed ID: 26939555
[No Abstract] [Full Text] [Related]
4. Choroidal neovascularisation secondary to serpiginous choroiditis: The value of OCT-angiography in diagnosis and response to therapy with aflibercept.
Campos Polo R; Rubio Sánchez C; Sánchez Trancón A
Arch Soc Esp Oftalmol (Engl Ed); 2019 Sep; 94(9):460-464. PubMed ID: 30733067
[TBL] [Abstract][Full Text] [Related]
5. Treat and extend regimen with aflibercept for choroidal neovascularization in angioid streaks.
Diago T
Eye (Lond); 2016 Apr; 30(4):637-9. PubMed ID: 26795418
[No Abstract] [Full Text] [Related]
6. Intravitreal aflibercept for choroidal neovascularisation complicating chronic central serous chorioretinopathy.
Broadhead GK; Chang A
Graefes Arch Clin Exp Ophthalmol; 2015 Jun; 253(6):979-81. PubMed ID: 25547617
[No Abstract] [Full Text] [Related]
7. Intravitreal aflibercept for myopic choroidal neovascularization.
Pece A
Graefes Arch Clin Exp Ophthalmol; 2016 Jul; 254(7):1435. PubMed ID: 26851951
[No Abstract] [Full Text] [Related]
8. Intravitreal Aflibercept Injection in Patients with Myopic Choroidal Neovascularization: The MYRROR Study.
Ikuno Y; Ohno-Matsui K; Wong TY; Korobelnik JF; Vitti R; Li T; Stemper B; Asmus F; Zeitz O; Ishibashi T;
Ophthalmology; 2015 Jun; 122(6):1220-7. PubMed ID: 25745875
[TBL] [Abstract][Full Text] [Related]
9. The Pitchfork Sign: A Novel OCT Feature of Choroidal Neovascularization in Tuberculosis.
Ramtohul P; Comet A; Denis D
Ophthalmol Retina; 2019 Jul; 3(7):615. PubMed ID: 31277802
[No Abstract] [Full Text] [Related]
10. Changes in cone-driven functions after intravitreal aflibercept injections in patients with age-related macular degeneration.
Nishimura T; Machida S; Hara Y
Doc Ophthalmol; 2020 Oct; 141(2):137-147. PubMed ID: 32100141
[TBL] [Abstract][Full Text] [Related]
11. INTRAVITREAL AFLIBERCEPT FOR CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION UNRESPONSIVE TO RANIBIZUMAB THERAPY.
Sarao V; Parravano M; Veritti D; Arias L; Varano M; Lanzetta P
Retina; 2016 Apr; 36(4):770-7. PubMed ID: 26398691
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal bevacizumab for choroidal neovascularisation in serpiginous choroiditis.
Parodi MB; Iacono P; La Spina C; Knutsson KA; Mansour A; Arevalo JF; Bandello F
Br J Ophthalmol; 2014 Apr; 98(4):519-22. PubMed ID: 24414400
[TBL] [Abstract][Full Text] [Related]
13. Long-term ranibizumab treatment for choroidal neovascularization secondary to serpiginous choroiditis.
Balaskas K; Ur Rehman S; D'Souza Y
Can J Ophthalmol; 2012 Oct; 47(5):e15-7. PubMed ID: 23036551
[No Abstract] [Full Text] [Related]
14. Quantitative OCT subanalysis of eyes with choroidal neovascularization switched from multiple injections of bevacizumab or ranibizumab to intravitreal aflibercept.
Hariri A; Diniz B; Fou LV; Lam LA; Nittala MG; Sadda SR
Ophthalmic Surg Lasers Imaging Retina; 2015 Feb; 46(2):195-200. PubMed ID: 25707044
[TBL] [Abstract][Full Text] [Related]
15. One-Year Results of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy.
Yamamoto A; Okada AA; Kano M; Koizumi H; Saito M; Maruko I; Sekiryu T; Iida T
Ophthalmology; 2015 Sep; 122(9):1866-72. PubMed ID: 26088619
[TBL] [Abstract][Full Text] [Related]
16. Subfoveal Choroidal Thickness during Aflibercept Therapy for Neovascular Age-Related Macular Degeneration: Twelve-Month Results.
Koizumi H; Kano M; Yamamoto A; Saito M; Maruko I; Sekiryu T; Okada AA; Iida T
Ophthalmology; 2016 Mar; 123(3):617-24. PubMed ID: 26686967
[TBL] [Abstract][Full Text] [Related]
17. Six-month results of intravitreal aflibercept injections for patients with polypoidal choroidal vasculopathy.
Hosokawa M; Shiraga F; Yamashita A; Shiragami C; Ono A; Shirakata Y; Kimura S; Shiode Y; Kawata T; Hosogi M; Fujiwara A; Morizane Y
Br J Ophthalmol; 2015 Aug; 99(8):1087-91. PubMed ID: 25712826
[TBL] [Abstract][Full Text] [Related]
18. ONE-YEAR RESULTS OF INTRAVITREAL AFLIBERCEPT FOR POLYPOIDAL CHOROIDAL VASCULOPATHY.
Hara C; Sawa M; Sayanagi K; Nishida K
Retina; 2016 Jan; 36(1):37-45. PubMed ID: 26383709
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal Aflibercept for Treatment-Resistant Neovascular Age-Related Macular Degeneration: 12-Month Safety and Efficacy Outcomes.
Chang AA; Broadhead GK; Hong T; Joachim N; Syed A; Schlub TE; Toth L; Peto T; Zhu M
Ophthalmic Res; 2015; 55(2):84-90. PubMed ID: 26637166
[TBL] [Abstract][Full Text] [Related]
20. Sequential Optical Coherence Tomographic Angiography for Diagnosis and Treatment of Choroidal Neovascularization in Multifocal Choroiditis.
Baumal CR; de Carlo TE; Waheed NK; Salz DA; Witkin AJ; Duker JS
JAMA Ophthalmol; 2015 Sep; 133(9):1087-90. PubMed ID: 26111344
[No Abstract] [Full Text] [Related]
[Next] [New Search]
